Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer: A Randomized Phase 2 Trial (IMPATIENS)

NCT07410559 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07410559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07410559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer: A Randomized Phase 2 Trial (IMPATIENS)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
July 1, 2031
Enrollment
189 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer